{"organizations": [], "uuid": "affe387a0ff620de2dfbb8fad2f9bca5e2bfb539", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-announces/brief-adverum-biotechnologies-announces-long-term-preclinical-efficacy-data-on-advm-022-gene-therapy-in-wet-amd-idUSFWN1S809D", "country": "US", "domain_rank": 408, "title": "BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.996, "site_type": "news", "published": "2018-05-01T21:07:00.000+03:00", "replies_count": 0, "uuid": "affe387a0ff620de2dfbb8fad2f9bca5e2bfb539"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-announces/brief-adverum-biotechnologies-announces-long-term-preclinical-efficacy-data-on-advm-022-gene-therapy-in-wet-amd-idUSFWN1S809D", "ord_in_thread": 0, "title": "BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amd", "sentiment": "negative"}, {"name": "adverum biotechnologies inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Adverum Biotechnologies Inc:\n* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD\n* ADVERUM BIOTECHNOLOGIES - 13-MONTH DATA SHOW EFFICACY, DURABILITY OF PROTEIN EXPRESSION FOLLOWING A SINGLE INTRAVITREAL ADMINISTRATION OF ADVM-022\n* ADVERUM BIOTECHNOLOGIES INC - ADVM-022 WAS WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS IN STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T21:07:00.000+03:00", "crawled": "2018-05-02T15:58:22.012+03:00", "highlightTitle": ""}